Literature DB >> 23380137

Changes in proteinase 3 anti-neutrophil cytoplasm autoantibody levels in early systemic granulomatosis with polyangiitis (Wegener's) may reflect treatment rather than disease activity.

N Rasmussen1, A Salmela, A Ekstrand, K de Groot, G Gregorini, J W Cohen Tervaert, W L Gross, A Wiik, D R W Jayne.   

Abstract

OBJECTIVES: To investigate the nature of the relationship between proteinase 3 anti-neutrophil cytoplasm autoantibody (PR3-ANCA) and relapse in patients with early systemic granulomatosis with polyangiitis (Wegener's) (GPA).
METHODS: Clinical data from 16 relapsing and 12 non-relapsing patients with early systemic GPA from a randomised clinical trial were correlated to monthly PR3-ANCA values over 18 months. Each sample was examined using 9 different enzyme-linked immunosorbent assays (ELISAs) to ensure reliability of ANCA results. PR3-ANCA peaks were identified by the highest sum of logarithmic transformation values from all assays in samples after remission.
RESULTS: A PR3-ANCA peak was identified in all relapsing and non-relapsing patients and coincided with relapse in all 14 evaluable relapsing patients. The monthly increment before the peak, however, was similar in relapsing and non-relapsing patients in all assays. Increments from remission to peak were higher in relapsing patients in 2/9 assays. PR3-ANCA values at entry and peak PR3-ANCA values were higher in relapsing patients in 3/9 and 2/9 assays, respectively. However, large overlaps of PR3-ANCA values prevented a distinction between relapsing and non-relapsing patients. The median time to reach peak values was 14 months in relapsing and 12 months in non-relapsing patients with scheduled termination of treatment at 12 months.
CONCLUSIONS: The predictive value for relapses of PR3-ANCA determinations confirm and extend previous reports. Although all relapses were related to PR3-ANCA increases, reduction or withdrawal of immunosuppression without relapse was also related to increases and may explain the lack of predictive value of sequential PR3-ANCA determinations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23380137

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  8 in total

Review 1.  [S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].

Authors:  Jan Henrik Schirmer; Peer M Aries; Kirsten de Groot; Bernhard Hellmich; Julia U Holle; Christian Kneitz; Ina Kötter; Peter Lamprecht; Ulf Müller-Ladner; Eva Reinhold-Keller; Christof Specker; Michael Zänker; Frank Moosig
Journal:  Z Rheumatol       Date:  2017-11       Impact factor: 1.372

2.  ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease.

Authors:  Michael J Kemna; Jan Damoiseaux; Jos Austen; Bjorn Winkens; Jim Peters; Pieter van Paassen; Jan Willem Cohen Tervaert
Journal:  J Am Soc Nephrol       Date:  2014-10-16       Impact factor: 10.121

3.  Diagnostic accuracy of antineutrophil cytoplasmic antibodies (ANCA) in predicting relapses of ANCA-associated vasculitis: systematic review and meta-analysis.

Authors:  Pankti Mehta; Anu Balakrishnan; Sanat Phatak; Mona Pathak; Sakir Ahmed
Journal:  Rheumatol Int       Date:  2022-08-30       Impact factor: 3.580

4.  Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.

Authors:  Lynn A Fussner; Amber M Hummel; Darrell R Schroeder; Francisco Silva; Rodrigo Cartin-Ceba; Melissa R Snyder; Gary S Hoffman; Cees G M Kallenberg; Carol A Langford; Peter A Merkel; Paul A Monach; Philip Seo; Robert F Spiera; E William St Clair; Nadia K Tchao; John H Stone; Ulrich Specks
Journal:  Arthritis Rheumatol       Date:  2016-07       Impact factor: 10.995

5.  Interventions for renal vasculitis in adults.

Authors:  Giles D Walters; Narelle S Willis; Tess E Cooper; Jonathan C Craig
Journal:  Cochrane Database Syst Rev       Date:  2020-01-13

6.  Biomarkers Predict Relapse in Granulomatosis with Polyangiitis.

Authors:  Patrick C P Hogan; Robert M O'Connell; Simone Scollard; Emmett Browne; Emer E Hackett; Conleth Feighery
Journal:  J Biomark       Date:  2014-04-30

7.  The European Vasculitis Society 2016 Meeting Report.

Authors:  Ingeborg M Bajema; Jan A Bruijn; Alina Casian; Maria C Cid; Elena Csernok; Emma van Daalen; Lorraine Harper; Thomas Hauser; Mark A Little; Raashid A Luqmani; Alfred Mahr; Cristina Ponte; Alan Salama; Mårten Segelmark; Kazuo Suzuki; Jan Sznajd; Y K Onno Teng; Augusto Vaglio; Kerstin Westman; David Jayne
Journal:  Kidney Int Rep       Date:  2017-09-21

8.  Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis.

Authors:  Gwen E Thompson; Lynn A Fussner; Amber M Hummel; Darrell R Schroeder; Francisco Silva; Melissa R Snyder; Carol A Langford; Peter A Merkel; Paul A Monach; Philip Seo; Robert F Spiera; E William St Clair; John H Stone; Ulrich Specks
Journal:  Front Immunol       Date:  2020-09-03       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.